Efficacy Comparison of Mepolizumab and Benralizumab in Patients with Severe Eosinophilic Asthma: A Retrospective Cohort Analysis - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Efficacy Comparison of Mepolizumab and Benralizumab in Patients with Severe Eosinophilic Asthma: A Retrospective Cohort Analysis

  • By

  • Wei-Chun Huang

  • Yi-Luen Shen

  • Wen-Chien Cheng

  • Chien-Wen Huang

  • Chia-Hung Chen

  • Chih- Yen Tu

  • Wu-Huei Hsu

  • February 10, 2026

Share

  • 1

    Mepolizumab and benralizumab are anti-IL-5 monoclonal antibodies used for severe eosinophilic asthma management.

  • 2

    Mepolizumab neutralizes IL-5, while benralizumab targets the IL-5 receptor, inducing eosinophil apoptosis.

  • 3

    No large-scale RCTs have directly compared the efficacy of mepolizumab and benralizumab in clinical settings.

  • 4

    This retrospective study aimed to evaluate the therapeutic efficacy and clinical remission rates of both agents.

  • 5

    Patients were followed for 12 months, assessing pulmonary function, asthma control, and acute exacerbations.

Original Source(s)

Efficacy Comparison of Mepolizumab and Benralizumab in Patients with Severe Eosinophilic Asthma: A Retrospective Cohort Analysis

  • by Wei-Chun Huang, Yi-Luen Shen, Wen-Chien Cheng, Chien-Wen Huang, Chia-Hung Chen, Chih- Yen Tu, Wu-Huei Hsu

  • February 10, 2026

Related Content

Top 10 evidence-based essentials in pulmonology

A structured framework of guidelines, trials, therapies, and tools used in clinical practice.

Top 10 FDA Recalls Physicians Should Know

A structured overview of recent FDA recalls, corrections, and alerts involving medications, ventilators, insulin delivery systems, cardiovascular devices, anesthesia products, and other equipment used in clinical practice.

Language Disparities in the PFT Lab: Implications for PFT Lab Quality Performance